Lentiviral δnp63α gene addition

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab

Cells1

Outcomes

Clonogenic potential

upin human cells1

1 study

Lentiviral δnp63α gene addition improves clonogenic potential in human cells.
“This led to an extended proliferative lifespan and improved clonogenic potential while maintaining cell stratification capability.”
CellsTP63-mutant cells evaluated alongside wild-type controlsself-inactivating lentiviral vector expressing ΔNp63α-EGFP under K14 regulatory elementsoral mucosa epithelial stem cells
Additive Gene and Stem Cell Therapy for Mutation-Independent Treatment of p63 Disorders
Preprints.org8 Oct 2026Preprint

Cell proliferative lifespan

upin human cells1

1 study

Lentiviral δnp63α gene addition increases cell proliferative lifespan in human cells.
“This led to an extended proliferative lifespan and improved clonogenic potential while maintaining cell stratification capability.”
CellsTP63-mutant cells evaluated alongside wild-type controlsself-inactivating lentiviral vector expressing ΔNp63α-EGFP under K14 regulatory elementsoral mucosa epithelial stem cells
Additive Gene and Stem Cell Therapy for Mutation-Independent Treatment of p63 Disorders
Preprints.org8 Oct 2026Preprint

Latest

1 in 12 months

Preprints.orgYesterday

Additive Gene and Stem Cell Therapy for Mutation-Independent Treatment of p63 Disorders

Preprint: experiments in human cellsInterventions

Paper

Lentiviral δnp63α gene addition

Outcomes

Latest

Additive Gene and Stem Cell Therapy for Mutation-Independent Treatment of p63 Disorders

Related